Review



trail neutralizing antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems trail neutralizing antibody
    Trail Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/Human+TRAIL%2FTNFSF10+Antibody/pmc13111737-305-11-15
    Average 94 stars, based on 27 article reviews
    trail neutralizing antibody - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Oncogenic KRAS-induces necroptotic priming of pancreatic neoplasia
    Article Snippet: Equal 957 amounts of protein were mixed with a final concentration of 1× LDS sample buffer (NP0008, 958 NuPAGE) and DTT (200mM) and then heated to 80 °C for 10 min.

    Article Title: Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity.
    Article Snippet: Camilo Faust Akl, Brian M. Andersen, Zhaorong Li, Federico Giovannoni, Martin Diebold, Liliana M. Sanmarco, Michael Kilian, Luca Fehrenbacher, Florian Pernin, Joseph M. Rone, Hong-Gyun Lee, Gavin Piester, Jessica E. Kenison, Joon-Hyuk Lee, Tomer Illouz, Carolina M. Polonio, Léna Srun, Jazmin Martinez, Elizabeth N. Chung, Anton Schüle, Agustin Plasencia, Lucinda Li, Kylynne Ferrara, Mercedes Lewandrowski, Craig A. Strathdee, Lorena Lerner, Christophe Quéva, Iain C. Clark, Benjamin Deneen, Judy Lieberman, David H. Sherr, Jack P. Antel, Michael A. Wheeler, Keith L. Ligon, E. Antonio Chiocca, Marco Prinz, David A. Reardon & Francisco J. Quintana1,12,16 ✉

    Article Title: Caspase 8 protects pancreatic neoplasia from KRAS-driven necroptotic priming
    Article Snippet: After another washing step, bound 890 antibodies were detected using chemiluminescent Amersham ECL Prime Western Blotting 891 Detection Reagent (RPN2235, Cytiva) or SuperSignalTM West Femto Maximum Sensitivity 892 Substrate (34095, Thermo Fisher).

    Article Title: Caspase 8 protects pancreatic neoplasia from KRAS-driven necroptotic priming
    Article Snippet: The following antibodies were used for tissue 648 stainings: Cytokeratin 19 (1:100, AHP1846, Bio rad antibodies (discontinued) and TROMA-649 III from Developmental Studies Hybridoma Bank Iowa University), CD45 (1:100, 14-0451-650 21 82, Invitrogen), Caspase 8 (1:200, ALX-804-447-C100, Enzo), cleaved caspase 3 (1:500, 9661, 651 Cell Signaling), pSTAT1 (1:50, 9167, Cell Signaling).

    Article Title: Development of Anti-OSCAR Antibodies for the Treatment of Osteoarthritis
    Article Snippet: Subchondral bone plate sclerosis and articular cartilage destruction were identified by safranin-O staining and measured using OsteoMeasureXP (OsteoMetrics, Inc., Atlanta, GA, USA), Adobe Photoshop (v19.1.3, San Jose, CA, USA), and an Olympus DP72 charge-coupled device camera (v2.1, Olympus Corporation, Tokyo, Japan).

    Enzyme-linked Immunosorbent Assay:

    Article Title: Multifaceted immune resistance landscapes in human oligodendrocytes protect against cytotoxic T cells and are dysregulated in MS brain cell subsets
    Article Snippet: The assay was performed according to the manufactureŕs instructions and samples were measured using the MAGPIX Luminex instrument (Merck). .. Supernatants of FluTC-MO3.13-A2-Luc co-cultures and anti-CD3/CD28 activated FluTC were further analyzed for the detection of IFNγ (Human IFN-γ ELISA Set, BD OptEIA, #555142), TNFα (Human TNF ELISA Set, BD OptEIA, #555212), Granzyme B (Human Granzyme B ELISA development kit, Mabtech, #3485-1H-20) and TRAIL (human TRAIL/TNFSF10 DuoSet ELISA, R&D Systems, #DY375-05) ( , ). ..

    Immunohistochemistry:

    Article Title: Development of Anti-OSCAR Antibodies for the Treatment of Osteoarthritis.
    Article Snippet: Subchondral bone plate sclerosis and articular cartilage destruction were identified by safranin-O staining and measured using OsteoMeasureXP (OsteoMetrics, Inc., Atlanta, GA, USA), Adobe Photoshop (v19.1.3, San Jose, CA, USA), and an Olympus DP72 charge-coupled device camera (v2.1, Olympus Corporation, Tokyo, Japan). .. For immunohistochemistry, the knee-joint sections were incubated overnight at 4 ◦C with a primary antibody specific for OSCAR (Cat. # PA5-47171, Thermo Fisher Scientific, 1:100 dilution), OPG (Cat# sc8468, Santa Cruz Biotechnology, 1:200 dilution), or TRAIL (Cat# AF1121, R&D Systems, 1:200 dilution). .. Immunoactivity was detected by using a DAB peroxidase substrate detection kit (Vector Laboratories, Inc., Newark, CA, USA), and the nuclei were counterstained with hematoxylin.

    Incubation:

    Article Title: Development of Anti-OSCAR Antibodies for the Treatment of Osteoarthritis.
    Article Snippet: Subchondral bone plate sclerosis and articular cartilage destruction were identified by safranin-O staining and measured using OsteoMeasureXP (OsteoMetrics, Inc., Atlanta, GA, USA), Adobe Photoshop (v19.1.3, San Jose, CA, USA), and an Olympus DP72 charge-coupled device camera (v2.1, Olympus Corporation, Tokyo, Japan). .. For immunohistochemistry, the knee-joint sections were incubated overnight at 4 ◦C with a primary antibody specific for OSCAR (Cat. # PA5-47171, Thermo Fisher Scientific, 1:100 dilution), OPG (Cat# sc8468, Santa Cruz Biotechnology, 1:200 dilution), or TRAIL (Cat# AF1121, R&D Systems, 1:200 dilution). .. Immunoactivity was detected by using a DAB peroxidase substrate detection kit (Vector Laboratories, Inc., Newark, CA, USA), and the nuclei were counterstained with hematoxylin.



    Similar Products

    human trail/tnfsf10 quantikine elisa kit  (Bio-Techne corporation)
    94
    Bio-Techne corporation human trail/tnfsf10 quantikine elisa kit
    Human Trail/Tnfsf10 Quantikine Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/Human+TRAIL%2FTNFSF10+Quantikine+ELISA+Kit/custom%40dtrl00%4042009727
    Average 94 stars, based on 1 article reviews
    human trail/tnfsf10 quantikine elisa kit - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    trail  (Proteintech)
    93
    Proteintech trail
    <t>Endothelial</t> <t>TRX2</t> restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated <t>TRAIL</t> signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.
    Trail, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/TRAIL+Antibody/pmc13676988-304-11-13
    Average 93 stars, based on 1 article reviews
    trail - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    anti trail  (Proteintech)
    93
    Proteintech anti trail
    <t>Endothelial</t> <t>TRX2</t> restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated <t>TRAIL</t> signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.
    Anti Trail, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/TRAIL+Antibody/10__1038_slash_s41419___026___09248___1-209-84-86
    Average 93 stars, based on 1 article reviews
    anti trail - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    human trail elisa kit  (RayBiotech inc)
    93
    RayBiotech inc human trail elisa kit
    <t>Endothelial</t> <t>TRX2</t> restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated <t>TRAIL</t> signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.
    Human Trail Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/Human+TRAIL+ELISA/pm42440253-60-2-7
    Average 93 stars, based on 1 article reviews
    human trail elisa kit - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    trail camera  (Sanwa Supply Inc)
    86
    Sanwa Supply Inc trail camera
    <t>Endothelial</t> <t>TRX2</t> restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated <t>TRAIL</t> signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.
    Trail Camera, supplied by Sanwa Supply Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/camera+trail/pmc13167871-124-17-19
    Average 86 stars, based on 1 article reviews
    trail camera - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    trail neutralizing antibody  (R&D Systems)
    94
    R&D Systems trail neutralizing antibody
    <t>Endothelial</t> <t>TRX2</t> restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated <t>TRAIL</t> signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.
    Trail Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/Human+TRAIL%2FTNFSF10+Antibody/pmc13111737-305-11-15
    Average 94 stars, based on 1 article reviews
    trail neutralizing antibody - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    trimeric trail  (Absolute Biotech Inc)
    86
    Absolute Biotech Inc trimeric trail
    <t>Endothelial</t> <t>TRX2</t> restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated <t>TRAIL</t> signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.
    Trimeric Trail, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/trail+trimeric/pm42031726-227-0-2
    Average 86 stars, based on 1 article reviews
    trimeric trail - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    trail  (R&D Systems)
    93
    R&D Systems trail
    (A) Luciferase-based cytotoxicity assay to validate the impact of selected HITs on FluTC-mediated MO3.13-A2-Luc killing. MO3.13-A2-Luc cells were transfected with IRG-specific pool of 30 siRNA (siTOOLs) and co-cultured with FluTC as described in . Graph indicates cytotoxicity/viability ratio normalized to Scr control. (B-C) Luminex-based cytokine analysis of the FluTC – MO3.13-A2-Luc cell co-cultures. MO3.13-A2-Luc cells transfected either with Scr siRNA or IRG-specific siRNA pool and (B) co-cultured with FluTC for 24 h or (C) cultured in CM. (B) MCP-1 and (C) IL-8 levels were depicted. (B) Each line represents an independent experiment; values indicate the average of (B) triplicates or (C) duplicates. (A) Representative data of at least 2 independent experiments with triplicates per sample. (A-C) Graphs show mean +/- SD. P-values were calculated using (A) two-tailed student’s t-test (B) Ratio-paired t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001. (D) Cytokine analysis to determine IFNγ, TNFα, FasL and <t>TRAIL</t> secretion by anti-CD3/CD28 activated FluTC. Values represent the mean ± SD of triplicates.
    Trail, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/Human+TRAIL%2FTNFSF10+DuoSet+ELISA/bio_rxiv__64898__2026__04__21__719872-251-42-47
    Average 93 stars, based on 1 article reviews
    trail - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    r d systems af631 α tubulin  (R&D Systems)
    93
    R&D Systems r d systems af631 α tubulin
    (A) Luciferase-based cytotoxicity assay to validate the impact of selected HITs on FluTC-mediated MO3.13-A2-Luc killing. MO3.13-A2-Luc cells were transfected with IRG-specific pool of 30 siRNA (siTOOLs) and co-cultured with FluTC as described in . Graph indicates cytotoxicity/viability ratio normalized to Scr control. (B-C) Luminex-based cytokine analysis of the FluTC – MO3.13-A2-Luc cell co-cultures. MO3.13-A2-Luc cells transfected either with Scr siRNA or IRG-specific siRNA pool and (B) co-cultured with FluTC for 24 h or (C) cultured in CM. (B) MCP-1 and (C) IL-8 levels were depicted. (B) Each line represents an independent experiment; values indicate the average of (B) triplicates or (C) duplicates. (A) Representative data of at least 2 independent experiments with triplicates per sample. (A-C) Graphs show mean +/- SD. P-values were calculated using (A) two-tailed student’s t-test (B) Ratio-paired t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001. (D) Cytokine analysis to determine IFNγ, TNFα, FasL and <t>TRAIL</t> secretion by anti-CD3/CD28 activated FluTC. Values represent the mean ± SD of triplicates.
    R D Systems Af631 α Tubulin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/Human+TRAIL+R2%2FTNFRSF10B+Antibody/pm41904147-229-131-131
    Average 93 stars, based on 1 article reviews
    r d systems af631 α tubulin - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    primary antibodies against trail  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc primary antibodies against trail
    (A) Luciferase-based cytotoxicity assay to validate the impact of selected HITs on FluTC-mediated MO3.13-A2-Luc killing. MO3.13-A2-Luc cells were transfected with IRG-specific pool of 30 siRNA (siTOOLs) and co-cultured with FluTC as described in . Graph indicates cytotoxicity/viability ratio normalized to Scr control. (B-C) Luminex-based cytokine analysis of the FluTC – MO3.13-A2-Luc cell co-cultures. MO3.13-A2-Luc cells transfected either with Scr siRNA or IRG-specific siRNA pool and (B) co-cultured with FluTC for 24 h or (C) cultured in CM. (B) MCP-1 and (C) IL-8 levels were depicted. (B) Each line represents an independent experiment; values indicate the average of (B) triplicates or (C) duplicates. (A) Representative data of at least 2 independent experiments with triplicates per sample. (A-C) Graphs show mean +/- SD. P-values were calculated using (A) two-tailed student’s t-test (B) Ratio-paired t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001. (D) Cytokine analysis to determine IFNγ, TNFα, FasL and <t>TRAIL</t> secretion by anti-CD3/CD28 activated FluTC. Values represent the mean ± SD of triplicates.
    Primary Antibodies Against Trail, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trail/pm41927038-91-4-8
    Average 86 stars, based on 1 article reviews
    primary antibodies against trail - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Endothelial TRX2 restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated TRAIL signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Thioredoxin‐2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation

    doi: 10.1002/advs.78304

    Figure Lengend Snippet: Endothelial TRX2 restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated TRAIL signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.

    Article Snippet: Primary antibodies included: TRX2 (1:5000, Invitrogen, PA5‐81102), TRX2 (1:5000, Abcam, ab185544), TRAIL (1:2000, Proteintech, 66756‐1‐Ig), TRAIL (1:2000, Thermo Fisher Scientific, 1J5S5), FOXO3a (1:3000, Proteintech, 10849‐1‐AP), VDAC1 (1:5000, Proteintech, 10866‐1‐AP), HSP60 (1:5000, Proteintech,15282‐1‐AP), Histone H3 (1:5000, Proteintech, 68345‐1‐Ig), Lamin B1 (1:5000, Selleck, F0523), Flag (1:5000, Beyotime, AF2855), HA (1:5000, Proteintech, HRP‐66006), GAPDH (1:20000, Servicebio, ZB15004), and β‐Actin (1:20000, Servicebio, ZB15001).

    Techniques: Analysis, Expressing, Western Blot, Transfection, Plasmid Preparation, Mutagenesis, Control, Enzyme-linked Immunosorbent Assay, Staining, Derivative Assay, Isolation, In Vitro Evaluation, In Vivo, Micro-CT, Tissue, Two Tailed Test

    TRAIL blockade restores angiogenesis–osteogenesis coupling and attenuates OVX‐induced osteoporotic bone loss. A) Representative 3D micro‐CT reconstructions of trabecular bone (top) and cortical bone (bottom) in distal femurs from mice in the Sham +IgG, ovariectomy (OVX) + IgG, and OVX + TRAIL Ab groups (n = 5). Scale bars, 200 µm (top) and 400 µm (bottom). B) Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), cortical thickness (Ct.Th), and bone mineral density (BMD) in the indicated groups. C) Representative H&E–stained distal femoral sections showing trabecular architecture and bone marrow adiposity. Scale bars, 200 µm. D, E) Representative immunofluorescence images of CD31 + vessels (red) and RUNX2 + osteoblast‐lineage cells (green) in the femoral metaphysis (D), with corresponding quantification of the percentage of RUNX2 + cells (E). GP, growth plate; Tb, trabecular bone. Scale bars, 50 µm. F, G) Representative TRAP–stained distal femoral sections (F) and histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (G). Scale bars, 50 µm. H, I) Representative immunofluorescence images of CD31 + vessels (red) and ATP6V1B1/B2 + mature osteoclasts (green) in the femoral metaphysis (H), with corresponding quantification of the ATP6V1B1/B2 + area relative to the total area (I). GP, growth plate; Tb, trabecular bone. Scale bars, 50 µm. All quantitative data are presented as means ± SEM. Statistical significance was determined by one‐way analysis of variance (ANOVA) with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Thioredoxin‐2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation

    doi: 10.1002/advs.78304

    Figure Lengend Snippet: TRAIL blockade restores angiogenesis–osteogenesis coupling and attenuates OVX‐induced osteoporotic bone loss. A) Representative 3D micro‐CT reconstructions of trabecular bone (top) and cortical bone (bottom) in distal femurs from mice in the Sham +IgG, ovariectomy (OVX) + IgG, and OVX + TRAIL Ab groups (n = 5). Scale bars, 200 µm (top) and 400 µm (bottom). B) Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), cortical thickness (Ct.Th), and bone mineral density (BMD) in the indicated groups. C) Representative H&E–stained distal femoral sections showing trabecular architecture and bone marrow adiposity. Scale bars, 200 µm. D, E) Representative immunofluorescence images of CD31 + vessels (red) and RUNX2 + osteoblast‐lineage cells (green) in the femoral metaphysis (D), with corresponding quantification of the percentage of RUNX2 + cells (E). GP, growth plate; Tb, trabecular bone. Scale bars, 50 µm. F, G) Representative TRAP–stained distal femoral sections (F) and histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (G). Scale bars, 50 µm. H, I) Representative immunofluorescence images of CD31 + vessels (red) and ATP6V1B1/B2 + mature osteoclasts (green) in the femoral metaphysis (H), with corresponding quantification of the ATP6V1B1/B2 + area relative to the total area (I). GP, growth plate; Tb, trabecular bone. Scale bars, 50 µm. All quantitative data are presented as means ± SEM. Statistical significance was determined by one‐way analysis of variance (ANOVA) with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.

    Article Snippet: Primary antibodies included: TRX2 (1:5000, Invitrogen, PA5‐81102), TRX2 (1:5000, Abcam, ab185544), TRAIL (1:2000, Proteintech, 66756‐1‐Ig), TRAIL (1:2000, Thermo Fisher Scientific, 1J5S5), FOXO3a (1:3000, Proteintech, 10849‐1‐AP), VDAC1 (1:5000, Proteintech, 10866‐1‐AP), HSP60 (1:5000, Proteintech,15282‐1‐AP), Histone H3 (1:5000, Proteintech, 68345‐1‐Ig), Lamin B1 (1:5000, Selleck, F0523), Flag (1:5000, Beyotime, AF2855), HA (1:5000, Proteintech, HRP‐66006), GAPDH (1:20000, Servicebio, ZB15004), and β‐Actin (1:20000, Servicebio, ZB15001).

    Techniques: Micro-CT, Analysis, Tissue, Staining, Immunofluorescence, H&E Stain

    Mechanistic illustration of endothelial TRX2–FOXO3a–mediated TRAIL secretion and osteoclastogenesis in osteoporotic bone loss. In the healthy skeletal vascular niche, TRX2 binds FOXO3a through a redox‐sensitive Cys90–Cys31 disulfide interface, retaining FOXO3a at the mitochondrial outer membrane and preventing its nuclear translocation in BVECs. By contrast, in the osteoporotic state, TRX2 loss or oxidative stress disrupts this disulfide‐mediated interaction, allowing FOXO3a nuclear translocation and activation of the TRAIL promoter. Increased endothelial TRAIL secretion remodels the extracellular vascular–skeletal niche by promoting osteoclastogenesis, enhancing osteoclastic bone resorption, and suppressing osteoblast‐associated osteogenesis, thereby driving osteoporosis progression.

    Journal: Advanced Science

    Article Title: Thioredoxin‐2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation

    doi: 10.1002/advs.78304

    Figure Lengend Snippet: Mechanistic illustration of endothelial TRX2–FOXO3a–mediated TRAIL secretion and osteoclastogenesis in osteoporotic bone loss. In the healthy skeletal vascular niche, TRX2 binds FOXO3a through a redox‐sensitive Cys90–Cys31 disulfide interface, retaining FOXO3a at the mitochondrial outer membrane and preventing its nuclear translocation in BVECs. By contrast, in the osteoporotic state, TRX2 loss or oxidative stress disrupts this disulfide‐mediated interaction, allowing FOXO3a nuclear translocation and activation of the TRAIL promoter. Increased endothelial TRAIL secretion remodels the extracellular vascular–skeletal niche by promoting osteoclastogenesis, enhancing osteoclastic bone resorption, and suppressing osteoblast‐associated osteogenesis, thereby driving osteoporosis progression.

    Article Snippet: Primary antibodies included: TRX2 (1:5000, Invitrogen, PA5‐81102), TRX2 (1:5000, Abcam, ab185544), TRAIL (1:2000, Proteintech, 66756‐1‐Ig), TRAIL (1:2000, Thermo Fisher Scientific, 1J5S5), FOXO3a (1:3000, Proteintech, 10849‐1‐AP), VDAC1 (1:5000, Proteintech, 10866‐1‐AP), HSP60 (1:5000, Proteintech,15282‐1‐AP), Histone H3 (1:5000, Proteintech, 68345‐1‐Ig), Lamin B1 (1:5000, Selleck, F0523), Flag (1:5000, Beyotime, AF2855), HA (1:5000, Proteintech, HRP‐66006), GAPDH (1:20000, Servicebio, ZB15004), and β‐Actin (1:20000, Servicebio, ZB15001).

    Techniques: Membrane, Translocation Assay, Activation Assay

    (A) Luciferase-based cytotoxicity assay to validate the impact of selected HITs on FluTC-mediated MO3.13-A2-Luc killing. MO3.13-A2-Luc cells were transfected with IRG-specific pool of 30 siRNA (siTOOLs) and co-cultured with FluTC as described in . Graph indicates cytotoxicity/viability ratio normalized to Scr control. (B-C) Luminex-based cytokine analysis of the FluTC – MO3.13-A2-Luc cell co-cultures. MO3.13-A2-Luc cells transfected either with Scr siRNA or IRG-specific siRNA pool and (B) co-cultured with FluTC for 24 h or (C) cultured in CM. (B) MCP-1 and (C) IL-8 levels were depicted. (B) Each line represents an independent experiment; values indicate the average of (B) triplicates or (C) duplicates. (A) Representative data of at least 2 independent experiments with triplicates per sample. (A-C) Graphs show mean +/- SD. P-values were calculated using (A) two-tailed student’s t-test (B) Ratio-paired t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001. (D) Cytokine analysis to determine IFNγ, TNFα, FasL and TRAIL secretion by anti-CD3/CD28 activated FluTC. Values represent the mean ± SD of triplicates.

    Journal: bioRxiv

    Article Title: Multifaceted immune resistance landscapes in human oligodendrocytes protect against cytotoxic T cells and are dysregulated in MS brain cell subsets

    doi: 10.64898/2026.04.21.719872

    Figure Lengend Snippet: (A) Luciferase-based cytotoxicity assay to validate the impact of selected HITs on FluTC-mediated MO3.13-A2-Luc killing. MO3.13-A2-Luc cells were transfected with IRG-specific pool of 30 siRNA (siTOOLs) and co-cultured with FluTC as described in . Graph indicates cytotoxicity/viability ratio normalized to Scr control. (B-C) Luminex-based cytokine analysis of the FluTC – MO3.13-A2-Luc cell co-cultures. MO3.13-A2-Luc cells transfected either with Scr siRNA or IRG-specific siRNA pool and (B) co-cultured with FluTC for 24 h or (C) cultured in CM. (B) MCP-1 and (C) IL-8 levels were depicted. (B) Each line represents an independent experiment; values indicate the average of (B) triplicates or (C) duplicates. (A) Representative data of at least 2 independent experiments with triplicates per sample. (A-C) Graphs show mean +/- SD. P-values were calculated using (A) two-tailed student’s t-test (B) Ratio-paired t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001. (D) Cytokine analysis to determine IFNγ, TNFα, FasL and TRAIL secretion by anti-CD3/CD28 activated FluTC. Values represent the mean ± SD of triplicates.

    Article Snippet: Supernatants of FluTC-MO3.13-A2-Luc co-cultures and anti-CD3/CD28 activated FluTC were further analyzed for the detection of IFNγ (Human IFN-γ ELISA Set, BD OptEIA, #555142), TNFα (Human TNF ELISA Set, BD OptEIA, #555212), Granzyme B (Human Granzyme B ELISA development kit, Mabtech, #3485-1H-20) and TRAIL (human TRAIL/TNFSF10 DuoSet ELISA, R&D Systems, #DY375-05) ( , ).

    Techniques: Luciferase, Cytotoxicity Assay, Transfection, Cell Culture, Control, Luminex, Two Tailed Test

    (A) FACS analysis to determine the surface expression of IFNG-R1, TNF-R1, TNF-R2, FAS, TRAIL-R1, and TRAIL-R2 in MO3.13-A2-Luc cells. Grey histograms represent the isotype control. (B) Impact of IRG knockdown on TRAIL-R2 surface expression in MO3.13-A2-Luc cells. Left panel: Representative overlay of histograms to compare TRAIL-R2 expression on IRG +/- MO3.13-A2-Luc cells. Right panel: Compiled data of mean fluorescence intensity (MFI) for TRAIL-R2 expression. (C) Real-time cytotoxicity assay (IncuCyte® SX5 System) to analyze TRAIL-induced apoptosis over 48 hours in IRG +/- MO3.13-A2-Luc cells. Incucyte® Cytotox-Red Dye was added to the transfected MO3.13 oligodendrocytes together with TRAIL treatment as an indicator of apoptosis. The graph shows total red object integrated intensity per well (RCU x µm²/Image). (D) Western blot analysis of total/cleaved caspase-3/8/9, TRAF2, phosho(p)/total TAK1, MKK4, JNK, NF-κB, pLKB1 and Bcl2 in IRG +/- MO3.13-A2-Luc cells upon 4 h treatment with TRAIL. Experiment was run in two separate blots each including Scr samples. Each HIT was shown in comparison to Scr sample analyzed in the same blot (Blot1: Scr, siSTK11, siKCNH8 and siABCA2; Blot2: Scr, siSLC1A3 and siCHRNA1). Representative data of (A & D) two, (B-C) three independent experiments. Values represent the mean ± SD. P-value was calculated using paired two-tailed Student’s t-test (* = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001).

    Journal: bioRxiv

    Article Title: Multifaceted immune resistance landscapes in human oligodendrocytes protect against cytotoxic T cells and are dysregulated in MS brain cell subsets

    doi: 10.64898/2026.04.21.719872

    Figure Lengend Snippet: (A) FACS analysis to determine the surface expression of IFNG-R1, TNF-R1, TNF-R2, FAS, TRAIL-R1, and TRAIL-R2 in MO3.13-A2-Luc cells. Grey histograms represent the isotype control. (B) Impact of IRG knockdown on TRAIL-R2 surface expression in MO3.13-A2-Luc cells. Left panel: Representative overlay of histograms to compare TRAIL-R2 expression on IRG +/- MO3.13-A2-Luc cells. Right panel: Compiled data of mean fluorescence intensity (MFI) for TRAIL-R2 expression. (C) Real-time cytotoxicity assay (IncuCyte® SX5 System) to analyze TRAIL-induced apoptosis over 48 hours in IRG +/- MO3.13-A2-Luc cells. Incucyte® Cytotox-Red Dye was added to the transfected MO3.13 oligodendrocytes together with TRAIL treatment as an indicator of apoptosis. The graph shows total red object integrated intensity per well (RCU x µm²/Image). (D) Western blot analysis of total/cleaved caspase-3/8/9, TRAF2, phosho(p)/total TAK1, MKK4, JNK, NF-κB, pLKB1 and Bcl2 in IRG +/- MO3.13-A2-Luc cells upon 4 h treatment with TRAIL. Experiment was run in two separate blots each including Scr samples. Each HIT was shown in comparison to Scr sample analyzed in the same blot (Blot1: Scr, siSTK11, siKCNH8 and siABCA2; Blot2: Scr, siSLC1A3 and siCHRNA1). Representative data of (A & D) two, (B-C) three independent experiments. Values represent the mean ± SD. P-value was calculated using paired two-tailed Student’s t-test (* = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001).

    Article Snippet: Supernatants of FluTC-MO3.13-A2-Luc co-cultures and anti-CD3/CD28 activated FluTC were further analyzed for the detection of IFNγ (Human IFN-γ ELISA Set, BD OptEIA, #555142), TNFα (Human TNF ELISA Set, BD OptEIA, #555212), Granzyme B (Human Granzyme B ELISA development kit, Mabtech, #3485-1H-20) and TRAIL (human TRAIL/TNFSF10 DuoSet ELISA, R&D Systems, #DY375-05) ( , ).

    Techniques: Expressing, Control, Knockdown, Fluorescence, Cytotoxicity Assay, Transfection, Western Blot, Comparison, Two Tailed Test

    (A-B) Impact of SIK3 on TRAIL-mediated MO3.13-A2-Luc killing was determined by (A) Luciferase-based cytotoxicity assay as described in supp and (B) real-time cytotoxicity assay as described in . Representative data of (A) three (B) two independent experiments. Values represent the mean ± SD. P-value was calculated using paired two-tailed Student’s t-test (* = p < 0.05, ** = p < 0.01).

    Journal: bioRxiv

    Article Title: Multifaceted immune resistance landscapes in human oligodendrocytes protect against cytotoxic T cells and are dysregulated in MS brain cell subsets

    doi: 10.64898/2026.04.21.719872

    Figure Lengend Snippet: (A-B) Impact of SIK3 on TRAIL-mediated MO3.13-A2-Luc killing was determined by (A) Luciferase-based cytotoxicity assay as described in supp and (B) real-time cytotoxicity assay as described in . Representative data of (A) three (B) two independent experiments. Values represent the mean ± SD. P-value was calculated using paired two-tailed Student’s t-test (* = p < 0.05, ** = p < 0.01).

    Article Snippet: Supernatants of FluTC-MO3.13-A2-Luc co-cultures and anti-CD3/CD28 activated FluTC were further analyzed for the detection of IFNγ (Human IFN-γ ELISA Set, BD OptEIA, #555142), TNFα (Human TNF ELISA Set, BD OptEIA, #555212), Granzyme B (Human Granzyme B ELISA development kit, Mabtech, #3485-1H-20) and TRAIL (human TRAIL/TNFSF10 DuoSet ELISA, R&D Systems, #DY375-05) ( , ).

    Techniques: Luciferase, Cytotoxicity Assay, Two Tailed Test

    Summary of molecular pathways involved in the downstream signaling of STK11/LKB1, KCNH8, ABCA2, SLC1A3/EAAT1 and/or CHRNA1/AChR-mediated immune resistance. Activation of caspase-3/-8/-9, MKK4, JNK1, NF-κB and expression of TRAF2, TRAIL-R2, IL-8 was experimentally depicted in this study, whereas the potential involvement of the other molecular components was deducted from the previous studies as described and referred in the results and discussion sections above. Colors of the lines depicting the regulatory networks are matched with colors of the IRG icons. Activating and inhibitory effects are indicated by arrows and blocked lines respectively. The figure was generated using biorender.com (Created in BioRender. Beckhove, P. (2026) https://BioRender.com/2adzain )

    Journal: bioRxiv

    Article Title: Multifaceted immune resistance landscapes in human oligodendrocytes protect against cytotoxic T cells and are dysregulated in MS brain cell subsets

    doi: 10.64898/2026.04.21.719872

    Figure Lengend Snippet: Summary of molecular pathways involved in the downstream signaling of STK11/LKB1, KCNH8, ABCA2, SLC1A3/EAAT1 and/or CHRNA1/AChR-mediated immune resistance. Activation of caspase-3/-8/-9, MKK4, JNK1, NF-κB and expression of TRAF2, TRAIL-R2, IL-8 was experimentally depicted in this study, whereas the potential involvement of the other molecular components was deducted from the previous studies as described and referred in the results and discussion sections above. Colors of the lines depicting the regulatory networks are matched with colors of the IRG icons. Activating and inhibitory effects are indicated by arrows and blocked lines respectively. The figure was generated using biorender.com (Created in BioRender. Beckhove, P. (2026) https://BioRender.com/2adzain )

    Article Snippet: Supernatants of FluTC-MO3.13-A2-Luc co-cultures and anti-CD3/CD28 activated FluTC were further analyzed for the detection of IFNγ (Human IFN-γ ELISA Set, BD OptEIA, #555142), TNFα (Human TNF ELISA Set, BD OptEIA, #555212), Granzyme B (Human Granzyme B ELISA development kit, Mabtech, #3485-1H-20) and TRAIL (human TRAIL/TNFSF10 DuoSet ELISA, R&D Systems, #DY375-05) ( , ).

    Techniques: Activation Assay, Expressing, Generated